$38.19
4.26% yesterday
Nasdaq, Nov 15, 10:14 pm CET
ISIN
US52490G1022
Symbol
LEGN
Sector
Industry

Legend Biotech Corp - ADR Stock price

$38.19
-6.72 14.96% 1M
-7.57 16.54% 6M
-21.98 36.53% YTD
-26.78 41.22% 1Y
-10.92 22.24% 3Y
+1.19 3.22% 5Y
+1.19 3.22% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
-1.70 4.26%
ISIN
US52490G1022
Symbol
LEGN
Sector
Industry

Key metrics

Market capitalization $7.01b
Enterprise Value $6.14b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 11.80
P/S ratio (TTM) P/S ratio 13.47
P/B ratio (TTM) P/B ratio 6.28
Revenue growth (TTM) Revenue growth 122.96%
Revenue (TTM) Revenue $520.18m
EBIT (operating result TTM) EBIT $-351.24m
Free Cash Flow (TTM) Free Cash Flow $-236.25m
Cash position $1.21b
EPS (TTM) EPS $-1.91
P/E forward negative
P/S forward 11.79
EV/Sales forward 10.39
Short interest 12.34%
Show more

Is Legend Biotech Corp - ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Legend Biotech Corp - ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

26 Analysts have issued a Legend Biotech Corp - ADR forecast:

24x Buy
92%
2x Hold
8%

Analyst Opinions

26 Analysts have issued a Legend Biotech Corp - ADR forecast:

Buy
92%
Hold
8%

Financial data from Legend Biotech Corp - ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
520 520
305% 305%
100%
- Direct Costs 215 215
-
41%
305 305
-
59%
- Selling and Administrative Expenses 220 220
101% 101%
42%
- Research and Development Expense 415 415
21% 21%
80%
-329 -329
-
-63%
- Depreciation and Amortization 22 22
-
4%
EBIT (Operating Income) EBIT -351 -351
21% 21%
-68%
Net Profit -348 -348
13% 13%
-67%

In millions USD.

Don't miss a Thing! We will send you all news about Legend Biotech Corp - ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Legend Biotech Corp - ADR Stock News

Neutral
Seeking Alpha
3 days ago
Legend Biotech Corporation (NASDAQ:LEGN ) Q3 2024 Earnings Conference Call November 12, 2024 8:00 AM ET Company Participants Jessie Yeung - Vice President of Investor Relations and Finance Ying Huang - Chief Executive Officer Lori Macomber - Chief Financial Officer Mythili Koneru - Chief Medical Officer Steve Gavel - Senior Vice President, Commercial Development, U.S. & Europe Conference Call P...
Neutral
GlobeNewsWire
9 days ago
SOMERSET, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a live webcast event for investors on Sunday, December 8, 2024, at 8:00 p.m. PT (11:00 p.m. ET) during the 66th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, CA.
Neutral
GlobeNewsWire
10 days ago
New data will showcase significantly increased and sustained minimal residual disease (MRD) negativity rates, reinforcing the potential of CARVYKTI to transform outcomes in refractory multiple myeloma
More Legend Biotech Corp - ADR News

Company Profile

Legend Biotech Corporation develops cell therapy solutions for cancer patients. The company was founded in 2014 and is based in Cayman Islands. The company operates as a subsidiary of Genscript Biotech Corporation.

Head office Cayman Islands
CEO Ying Huang
Employees 1,826
Founded 2014
Website www.legendbiotech.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today